Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Semiconductors

Intel Accelerates Sweeping Restructuring Under New Leadership

Robert Sasse by Robert Sasse
September 13, 2025
in Semiconductors, TecDAX, Tech & Software, Turnaround
0
Intel Stock
0
SHARES
140
VIEWS
Share on FacebookShare on Twitter

Intel Corporation finds itself navigating a profound crisis, a reality widely acknowledged across the tech sector. Under the direction of CEO Lip-Bu Tan, the semiconductor giant is accelerating the pace of its comprehensive overhaul. A fresh wave of significant leadership changes announced this Monday underscores that the company’s transformation initiative is far from complete. The critical question remains whether this aggressive strategy can ultimately return Intel to a trajectory of sustained growth.

Strategic Appointments Reshape Top Management

The most notable departure is that of Michelle Johnston Holthaus, who is leaving the company after a tenure exceeding thirty years. Following the abrupt dismissal of Pat Gelsinger in December 2024, Holthaus had briefly served as co-CEO and was recognized as one of the most influential figures within the corporation.

Her successor is being recruited externally. Kevork Kechichian is moving from Arm Holdings to take command of Intel’s crucial data center division. This appointment is viewed as a strategic masterstroke, given Arm’s established reputation as an innovator in advanced processor technology. In a parallel move, Jim Johnson, a veteran with four decades of experience at Intel, has been named to lead the PC chip business unit.

A Radical Operational Overhaul

These executive shifts are a deliberate component of Tan’s clear-cut plan. The corporate leadership structure is being radically streamlined, with the principal chip divisions now set to report directly to the CEO. Concurrently, the establishment of a new “Central Engineering Group,” to be headed by Srinivasan Iyengar, signals a serious commitment to Intel’s foundry aspirations.

The overarching objective is a fundamental shift in Intel’s business model: to not only manufacture its own semiconductors but also to become a production partner for external clients. This move represents a direct challenge to the current market leader, Taiwan Semiconductor Manufacturing Company (TSMC).

Should investors sell immediately? Or is it worth buying Intel?

Aggressive Cost-Cutting Measures Continue

This extensive restructuring is unfolding against a backdrop of intense financial pressure. The company is proceeding with plans to eliminate approximately 25,000 positions by the end of the year—a reduction equivalent to 22% of its workforce. The financial results for Q2 2025 were sobering; revenue remained flat year-over-year at $12.9 billion, culminating in a net loss of $0.67 per share.

Adding another layer of complexity is the involvement of the U.S. government. In an unprecedented state intervention into a major technology firm, the Trump administration secured a 9.9% stake in Intel for $8.9 billion in August.

A High-Stakes Balancing Act

Market analysts are offering mixed perspectives on the leadership overhaul. On one hand, Kechichian brings invaluable expertise from the Arm ecosystem. On the other, Intel is sacrificing Holthaus’s deep institutional knowledge and extensive internal networks, built over decades.

The company is now engaged in a race against time. As key rivals AMD and Nvidia capitalize on booming AI markets, Intel remains focused on the arduous task of executing its foundry strategy. The efficacy of Tan’s radical approach will be measured in the company’s performance over the coming quarters.

Ad

Intel Stock: Buy or Sell?! New Intel Analysis from February 7 delivers the answer:

The latest Intel figures speak for themselves: Urgent action needed for Intel investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Intel: Buy or sell? Read more here...

Tags: Intel
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

OneSpan Stock
Cyber Security

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026
Great Lakes Dredge, Dock Stock
Analysis

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

February 7, 2026
Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Next Post
MSCI World ETF Stock

Global Index Performance Fueled by Technology Titans

Coinbase Stock

Coinbase Escalates Legal Battle with SEC Over Document Destruction Allegations

Oxford Lane Capital Stock

Oxford Lane Capital's Post-Consolidation Valuation Unveils Surprising Figures

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com